TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 408142

Group type: COMPARATOR
Intervention: Intravenous glucose on day 4 (n = 6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.1 mg glucagon with glucose load on day 4 (n = 5)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon with glucose load on day 4 (n = 6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Glucagon infused alone on day 4 of fast (n = 5)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Glucagon administered 24 h after glucose load (n = 6)
Number of subjects: 37
Study: 31707788

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 28589231

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (POBA)
Number of subjects: 135
Study: 26051429

Group type: EXPERIMENTAL
Intervention: Olive leaf extract (OLE) (51 mg oleuropein; 10 mg HT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 18
Study: 23644088

Group type: EXPERIMENTAL
Intervention: Optional side branch (SB) stenting
Number of subjects: 413

Group type: COMPARATOR
Intervention: Main vessel (MV) and side branch (SB) stenting
Number of subjects: 413
Study: 21083582

Group type: EXPERIMENTAL
Intervention: Itopride 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19690227

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: On-demand use of antibiotics
Number of subjects: 4
Study: 17224857

Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/1 mg estradiol (DRSP/E2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15129751

Group type: EXPERIMENTAL
Intervention: Surrounding frames (various types including squares, parallel lines, squares with gaps, and squares with circular contours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not explicitly defined in the abstract)
Number of subjects: 0
Study: 11885213

Group type: EXPERIMENTAL
Intervention: Outpatient women-centered substance abuse treatment program
Number of subjects: 15
Study: 9782691

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (treatment group)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Traditional pharmacy care (control group)
Number of subjects: 133
Study: 7869251

Group type: EXPERIMENTAL
Intervention: L-NMMA (nitric oxide synthase blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine + L-NMMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (contralateral forearm without treatment)
Number of subjects: 0
Study: 3044476

Group type: EXPERIMENTAL
Intervention: 3 fractions per week
Number of subjects: 411

Group type: COMPARATOR
Intervention: 2 fractions per week
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 6 fractions
Number of subjects: 411

Group type: COMPARATOR
Intervention: 12 fractions
Number of subjects: 411
Study: 31102326

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 572

Group type: COMPARATOR
Intervention: Glimepiride (1-3 mg/day)
Number of subjects: 572
Study: 31129812

Group type: EXPERIMENTAL
Intervention: L-selenomethionine (L-Se-Met) 83 mcg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 45
Study: 28412086

Group type: EXPERIMENTAL
Intervention: Tocolysis
Number of subjects: 803
Study: 26056515

Group type: EXPERIMENTAL
Intervention: Regular beer (up to 660 ml) followed by water ad-libitum (BW)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mineral water ad-libitum (W)
Number of subjects: 16
Study: 24335629

Group type: EXPERIMENTAL
Intervention: SECURE-C Cervical Artificial Disc
Number of subjects: 380

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 380
Study: 21659972

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg once a week) + 600 mg calcium + 400 IU vitamin D
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (600 mg calcium + 400 IU vitamin D)
Number of subjects: 80
Study: 19191779

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone (GnRH) analogues
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple tourniquets
Number of subjects: 40
Study: 16534012

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Regression or absence of ECG LVH by CP in patients without diabetes
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Regression of ECG LVH in patients with diabetes
Number of subjects: 9193
Study: 12969167

Group type: EXPERIMENTAL
Intervention: Fosinopril, 10 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 11015481

Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid (Mono) diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: High carbohydrate (CHO) diet
Number of subjects: 19
Study: 8823331

Group type: EXPERIMENTAL
Intervention: PIXY321 250 micrograms/m2/d
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PIXY321 500 micrograms/m2/d
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PIXY321 750 micrograms/m2/d
Number of subjects: 13
Study: 1333909

Group type: EXPERIMENTAL
Intervention: Suspension injection alone (A, n = 54)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Suspension injection + TAE using gelatin sponge (B, n = 29)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: TAE followed by suspension injection (C, n = 34)
Number of subjects: 180

Group type: COMPARATOR
Intervention: TAE alone (D, n = 63)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regimen A vs Regimen D for tumors ≥ 5 cm
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regimen A vs Regimen D for tumors < 5 cm
Number of subjects: 180
Study: 6385745

Group type: EXPERIMENTAL
Intervention: Intensive nasogastric tube feedings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Optimal oral nutrition
Number of subjects: 40
Study: 29793970

Group type: EXPERIMENTAL
Intervention: Mobile mindfulness programme
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telephone mindfulness programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Education programme
Number of subjects: 80
Study: 29324495

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg for 15 minutes followed by 2 mg/kg/h)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (20 mg/kg over 15 minutes followed by 20 mg/kg/h)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 135
Study: 26792372

Group type: EXPERIMENTAL
Intervention: Intravenous Zoledronic acid
Number of subjects: 251
Study: 23737075

Group type: EXPERIMENTAL
Intervention: Stepped-care programme (n=93)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Usual care (n=92)
Number of subjects: 185
Study: 22697439

Group type: EXPERIMENTAL
Intervention: Mindfulness skills training intervention (4 sessions over 21 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No-intervention (control) condition
Number of subjects: 53
Study: 20080983

Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18852662

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 106
Study: 12575396

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) combined with captopril (CAP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Dexamethasone and interferon (Control)
Number of subjects: 109
Study: 9394054

Group type: EXPERIMENTAL
Intervention: Supportive coaching and interventions over the course of the academic year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supportive coaching)
Number of subjects: 0
Study: 7893247

Group type: EXPERIMENTAL
Intervention: Adult Attachment Interview (AAI)
Number of subjects: 62
Study: 2439255

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dextran‐40
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intraoperative colloids (0.5 g/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Immediate urinary onset patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Delayed urinary onset patients
Number of subjects: 17
Study: 31355931

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 29101402

Group type: EXPERIMENTAL
Intervention: Sertraline (n=102) at an initial dose of 50 mg/d, escalated to a maximum of 200 mg/d for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo (n=99) for 12 weeks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Sertraline (n=102)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 201
Study: 25568414

Group type: EXPERIMENTAL
Intervention: Patient-specific cutting guides (PSCG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 140
Study: 23293335

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (1 infusion)
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (3 infusions)
Number of subjects: 1367
Study: 20825367

Group type: EXPERIMENTAL
Intervention: iNO 80 p.p.m. + GC (2mg/kg, hydrocortisone)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (nitrogen) + GC (2mg/kg, hydrocortisone)
Number of subjects: 15
Study: 18288090

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Next-step treatment after citalopram
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Third-step treatment among those with unsatisfactory benefit to citalopram and one next-step pharmacotherapy
Number of subjects: 1554
Study: 16547529

Group type: EXPERIMENTAL
Intervention: Broad-based immunomodulatory agents (e.g. intravenous immunoglobulin, thalidomide, pentoxifylline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled mortality studies
Number of subjects: 0
Study: 12615589

Group type: EXPERIMENTAL
Intervention: Two-stage intervention comprising screening and a brief standardized nursing assessment and referral.
Number of subjects: 345

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 345
Study: 10967260

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lactococcus lactis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (ethyl cellulose)
Number of subjects: 30
Study: 9189647

Group type: EXPERIMENTAL
Intervention: Soybean products
Number of subjects: 34

Group type: COMPARATOR
Intervention: Skim milk products and soy oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: 2% cows' milk products
Number of subjects: 34
Study: 1439112

Group type: EXPERIMENTAL
Intervention: Thymostimulin (Tp-1) treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 29239030

Group type: EXPERIMENTAL
Intervention: Bodyweight neuromuscular exercises (EG, n = 86)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard tactical-technical exercises (CG, n = 74)
Number of subjects: 160
Study: 27557913

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (Cervitec Plus) applied after resin infiltration (DMG, ICON)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Resin infiltration (DMG, ICON) without chlorhexidine varnish
Number of subjects: 45
Study: 25904773

Group type: EXPERIMENTAL
Intervention: Low-glucose regimen (Physioneal, Extraneal, Nutrineal)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dianeal (control group)
Number of subjects: 80
Study: 24336664

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (10 sessions)
Number of subjects: 94
Study: 20513116

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (long-term exposure)
Number of subjects: 0
Study: 17997712

Group type: EXPERIMENTAL
Intervention: Finite element analysis (FEA) assessing bone mechanical properties, volumetric bone density, and microarchitecture
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Principal components analysis (PCA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bone mechanical properties assessed by microFE
Number of subjects: 66
Study: 16946640

Group type: EXPERIMENTAL
Intervention: Specific spinal stabilization exercises
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 97
Study: 12904183

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 and 1.0 MAC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 and 1.0 MAC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desflurane (0.5 and 1.0 MAC)
Number of subjects: 36
Study: 10673735

Group type: EXPERIMENTAL
Intervention: Newer antihypertensive agents (amlodipine and perindopril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older antihypertensive agents (bendroflumethiazide and atenolol)
Number of subjects: 0
Study: 9104123

Group type: EXPERIMENTAL
Intervention: Cairwave Therapy System
Number of subjects: 12

Group type: COMPARATOR
Intervention: Airwave mattress
Number of subjects: 12
Study: 1490203

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rh‐Epo)
Number of subjects: 28
Study: 3886122

Group type: EXPERIMENTAL
Intervention: 34.5 Gy of radiotherapy (in 19 days overall) followed by surgery
Number of subjects: 410

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 410

Group type: COMPARATOR
Intervention: Both therapeutic regimens
Number of subjects: 410
Study: 31584782

Group type: EXPERIMENTAL
Intervention: Halobetasol 0.01% lotion
Number of subjects: 234

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 234
Study: 30334410

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective cervical nerve root block
Number of subjects: 60

Group type: COMPARATOR
Intervention: X-ray C-arm-guided cervical spinal block
Number of subjects: 60
Study: 27181998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily (S100)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily (M1000)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily (M1700)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily plus Metformin 500 mg twice daily (S100/M1000)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily plus Metformin 850 mg twice daily (S100/M1700)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: High-dose metformin groups
Number of subjects: 744
Study: 24254248

Group type: EXPERIMENTAL
Intervention: Exposure to cancer-related direct-to-consumer advertising (DTCA)
Number of subjects: 0
Study: 22574560

Group type: EXPERIMENTAL
Intervention: PIRRT (SLEDD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PIRRT (SLEDD-f)
Number of subjects: 60
Study: 19436935

Group type: EXPERIMENTAL
Intervention: One-on-one telephone-based counseling and mailed education (Motivational interviewing)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Mailed education
Number of subjects: 879
Study: 19077735

Group type: EXPERIMENTAL
Intervention: Core Strength Training (CST) for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Core Strength Training (Control)
Number of subjects: 28
Study: 16435705

Group type: EXPERIMENTAL
Intervention: Dynamic breast model with pulsating lumps (augmented tactile feedback)
Number of subjects: 48
Study: 12618970

Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin once daily for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin stearate every 6 hours for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison between azithromycin and erythromycin
Number of subjects: 60
Study: 10095156

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8607228

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2084
Study: 1849732

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms kg-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Granisetron and Lorazepam (combined)
Number of subjects: 12
Study: 6303001

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg propranolol (Dociton)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg metoprolol (Beloc)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 10
Study: 31418425

Group type: EXPERIMENTAL
Intervention: Call center intervention providing information about MR medications
Number of subjects: 287042

Group type: EXPERIMENTAL
Intervention: Call center intervention
Number of subjects: 287042
Study: 28216282

Group type: EXPERIMENTAL
Intervention: Quitters (smokers who stopped smoking)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Continuing smokers (control group)
Number of subjects: 122
Study: 27330284

Group type: EXPERIMENTAL
Intervention: SPACE for COPD
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 24518752

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with virgin olive oil
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with mixed nuts
Number of subjects: 191
Study: 21983476

Group type: EXPERIMENTAL
Intervention: Skills for Improving Distress Intolerance (SIDI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 76
Study: 19299533

Group type: EXPERIMENTAL
Intervention: Tedisamil (100 mg bid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of tedisamil and verapamil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil (180 mg bid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tedisamil and verapamil combination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Verapamil and tedisamil combination
Number of subjects: 12
Study: 18024630

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET imaging
Number of subjects: 0
Study: 16053997

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects) during HUT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension) during HUT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes) during HUT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes) during HUT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects) during reactive hyperemia to DCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 1 (hypertension) during reactive hyperemia to DCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 2 (diabetes) during reactive hyperemia to DCA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 3 (hypertension and diabetes) during reactive hyperemia to DCA
Number of subjects: 48
Study: 12113382

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol 9 microg twice daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral zafirlukast 20 mg twice daily
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline 400 mg once daily
Number of subjects: 64
Study: 9925123

Group type: EXPERIMENTAL
Intervention: High-fiber meal (15.7 g fiber) containing barley pasta enriched with beta-glucan
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fiber meal (5.0 g fiber) containing pasta made with wheat flour
Number of subjects: 11
Study: 7672999

Group type: EXPERIMENTAL
Intervention: Intramuscular 800 mg (5 ml) human immunoglobulin (1x/week)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Panthenol (4x10 ml/day) and nystatin (4 x 1 ml/day)
Number of subjects: 42
Study: 2258786

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study: 7234648

Group type: EXPERIMENTAL
Intervention: Diltiazem (D) 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 31446157

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-receptor antagonist)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 31640990

Group type: EXPERIMENTAL
Intervention: Telemedicine for diabetes management
Number of subjects: 48
Study: 28948720

Group type: EXPERIMENTAL
Intervention: Behavioral weight management program combined with smoking cessation program (including behavioral counseling and nicotine replacement)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Smoking cessation program alone (comparison group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Intervention participants who were abstinent at 6 months
Number of subjects: 330
Study: 25576215

Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 328

Group type: COMPARATOR
Intervention: HBsAg-Eng
Number of subjects: 328